- Home
- CRBG vs NTRA Comparison
CRBG vs NTRA Comparison
Compare CRBG & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRBG
- NTRA
- Stock Information
- Founded
- CRBG 1957
- NTRA 2003
- Country
- CRBG United States
- NTRA United States
- Employees
- CRBG N/A
- NTRA N/A
- Industry
- CRBG Life Insurance
- NTRA Medical Specialities
- Sector
- CRBG Finance
- NTRA Health Care
- Exchange
- CRBG Nasdaq
- NTRA Nasdaq
- Market Cap
- CRBG 18.0B
- NTRA 21.5B
- IPO Year
- CRBG 2022
- NTRA 2015
- Fundamental
- Price
- CRBG $32.64
- NTRA $171.86
- Analyst Decision
- CRBG Buy
- NTRA Strong Buy
- Analyst Count
- CRBG 14
- NTRA 16
- Target Price
- CRBG $37.43
- NTRA $185.56
- AVG Volume (30 Days)
- CRBG 2.7M
- NTRA 1.2M
- Earning Date
- CRBG 07-30-2025
- NTRA 08-07-2025
- Dividend Yield
- CRBG 2.95%
- NTRA N/A
- EPS Growth
- CRBG N/A
- NTRA N/A
- EPS
- CRBG 1.17
- NTRA N/A
- Revenue
- CRBG $16,549,000,000.00
- NTRA $1,831,000,000.00
- Revenue This Year
- CRBG $10.18
- NTRA $19.92
- Revenue Next Year
- CRBG $7.65
- NTRA $16.02
- P/E Ratio
- CRBG $27.73
- NTRA N/A
- Revenue Growth
- CRBG N/A
- NTRA 51.50
- 52 Week Low
- CRBG $23.69
- NTRA $92.14
- 52 Week High
- CRBG $35.36
- NTRA $183.00
- Technical
- Relative Strength Index (RSI)
- CRBG 53.83
- NTRA 66.42
- Support Level
- CRBG $31.71
- NTRA $161.39
- Resistance Level
- CRBG $33.34
- NTRA $169.17
- Average True Range (ATR)
- CRBG 0.67
- NTRA 4.86
- MACD
- CRBG -0.13
- NTRA 0.57
- Stochastic Oscillator
- CRBG 49.73
- NTRA 90.95
About CRBG Corebridge Financial Inc.
Corebridge Financial Inc provides retirement solutions and insurance products in the United States. It offers a broad set of products and services through five segments Individual Retirement, Group Retirement, Life Insurance, Institutional Markets businesses, Corporate and Other. The majority of its revenue derives from the Individual Retirement segment.
About NTRA Natera Inc.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.